Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
HLS Therapeutics Inc (DE:74D)
FRANKFURT:74D
HLS Therapeutics Inc (74D) Stock Price & Analysis
0 Followers
74D Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.04 - €4.22
Previous Close€2.1
Volume0.00
Average Volume (3M)N/A
Market Cap
€66.58M
Enterprise Value€55.05M
Total Cash (Recent Filing)$19.44M
Total Debt (Recent Filing)$6.88M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Aug 08, 2024EPS Estimate
-€0.14Last Dividend Ex-Date
Apr 27, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding31,814,547
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-1.25
Price to Sales (P/S)1.15
Price to Cash Flow (P/CF)5.40
P/FCF Ratio3.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.91
Enterprise Value/Gross Profit0.99
Enterprise Value/Ebitda5.05
Forecast
1Y Price Target
€3.54Price Target Upside73.59% Upside
Rating ConsensusHold
Number of Analyst Covering4
HLS Therapeutics Inc News
PremiumCompany Announcements
HLS Therapeutics Schedules Q2 Financial Results Call
PremiumCompany Announcements
HLS Therapeutics Divests Royalty Interest, Updates GuidancePremiumCompany Announcements
HLS Therapeutics Shareholders Back Board and Auditors
PremiumCompany Announcements
HLS Therapeutics Boosts Treatment Adherence with Support Programs
PremiumCompany Announcements
HLS Therapeutics Faces Q1 Challenges, Ends Pfizer DealPremiumCompany Announcements
HLS Therapeutics Announces Q1 2024 Financial Results
PremiumCompany Announcements
HLS Therapeutics Showcases at Investor Conference
PremiumCompany Announcements
HLS’s VASCEPA Shows Promise for Heart Disease PatientsBulls Say, Bears Say
Bulls Say
Assumed ObligationsDRI also assumed $18.5 million of potential future milestone payment obligations for which HLS would have been on the hook.
Strategic SaleHLS announced the sale of its Xenpozyme royalty to DRI Healthcare Trust.
Upfront PaymentDRI paid $13.25M upfront with $14.0M in sales-based milestones potentially payable to HLS.
Bears Say
Earnings1Q-24 results missed Bloom Burton and consensus expectations.
Operational ChangesThe company announced it is terminating its Vascepa primary care promotional activities.
Revenue Guidance2024 revenue guidance was reduced to $60-$62M from previously $63.5-$66.5 million.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.57% Other Institutional Investors
98.43% Public Companies and
Individual Investors
74D FAQ
What was HLS Therapeutics Inc’s price range in the past 12 months?
HLS Therapeutics Inc lowest stock price was €2.04 and its highest was €4.22 in the past 12 months.
What is HLS Therapeutics Inc’s market cap?
Currently, no data Available
When is HLS Therapeutics Inc’s upcoming earnings report date?
HLS Therapeutics Inc’s upcoming earnings report date is Aug 08, 2024 which is in 12 days.
How were HLS Therapeutics Inc’s earnings last quarter?
HLS Therapeutics Inc released its earnings results on May 09, 2024. The company reported -€0.174 earnings per share for the quarter, missing the consensus estimate of -€0.146 by -€0.028.
Is HLS Therapeutics Inc overvalued?
According to Wall Street analysts HLS Therapeutics Inc’s price is currently Undervalued.
Does HLS Therapeutics Inc pay dividends?
HLS Therapeutics Inc pays a Quarterly dividend of €0.03 which represents an annual dividend yield of N/A. See more information on HLS Therapeutics Inc dividends here
What is HLS Therapeutics Inc’s EPS estimate?
HLS Therapeutics Inc’s EPS estimate is -€0.14.
How many shares outstanding does HLS Therapeutics Inc have?
Currently, no data Available
What happened to HLS Therapeutics Inc’s price movement after its last earnings report?
HLS Therapeutics Inc reported an EPS of -€0.174 in its last earnings report, missing expectations of -€0.146. Following the earnings report the stock price went up 1.282%.
Which hedge fund is a major shareholder of HLS Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:74D
---
HLS Therapeutics Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€3.54 (73.59% Upside)
€3.54 (73.59% Upside)
Insider Transactions
Bought Shares
Worth C$10.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.43%
12-Months-Change
Fundamentals
Return on Equity
-26.66%
Trailing 12-Months
Asset Growth
-15.55%
Trailing 12-Months
Company Description
HLS Therapeutics Inc
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada and the United States.
---
74D Stock 12 Month Forecast
Average Price Target
€3.54
▲(73.59% Upside)
Technical Analysis
Best Analysts Covering 74D
1 Year
1 Year Success Rate
9/30 ratings generated profit
1 Year Average Return
+5.50%
reiterated a buy rating 25 days ago
Copying David Martin PhD's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of +5.50% per trade.
---